Veracyte’s Decipher Test Predicts Abiraterone Benefit in Very High-Risk Prostate Cancer Study

Bitget2026/10/23 08:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Veracyte’s Decipher Prostate test predicted benefit from adding abiraterone to hormone therapy in men with very high-risk, nonmetastatic prostate cancer.
The retrospective analysis of the Phase III STAMPEDE trial included 401 patients; higher Decipher scores identified greater benefit in reducing cancer spread.
Findings support using the test before treatment intensification to weigh potential benefits against abiraterone’s added side effects and treatment burden.
Results will be presented at the European Society for Medical Oncology Congress on October 24, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230400PRIMZONEFULLFEED9851884) on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Veracyte’s Decipher Test Predicts Abiraterone Benefit in Very High-Risk Prostate Cancer Study

You may also like

Crypto prices